© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Delivering Personalized Medicine Through Molecular Diagnostics and Innovation
Posted 30th August 2019

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation

Interpace Diagnostics provides molecular tests and pathology services to physicians and hospitals for various types of cancer. Earlier this year, the company found success in AI’s Global Excellence Awards 2019 where they were selected as the Most Innovative Molecular Diagnostics Company 2019 – Northeast USA.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation

Interpace Diagnostics provides molecular tests and pathology services to physicians and hospitals for various types of cancer. Earlier this year, the company found success in AI’s Global Excellence Awards 2019 where they were selected as the Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Following this win, we caught up with Chief Commercial Officer, Greg Richard who kindly provided us with a glimpse into the award-winning services the team consistently delivers.

Since their inception, Interpace Diagnostics has developed and commercialized molecular diagnostics tests for early detection of cancer in lesions where risk is uncertain by routine clinical methods. Today, Interpace Diagnostics currently has five marketed products for various indications: ThyGeNEXT, ThyraMIR, PancraGEN, RespriDx and BarreGEN. Going into further detail, Greg begins by informing us of the key qualities of each of these products and explaining what each one is used for.

“ThyGeNEXT and ThyraMIR are used to determine whether or not a patient has risk factors for thyroid cancer; it helps assist physicians in making decisions regarding surgical intervention. PancraGEN, the company’s pancreatic cancer risk classifier, is performed on an integrated molecular pathology platform and assists physicians in identifying those patients with pancreatic cysts, solid lesions, and biliary strictures that are at risk of developing pancreatic or biliary cancer. PancraGEN has been used in over 40,000 patient samples and represents the largest data repository of molecular data on pancreatic cysts in the U.S. RespriDx is used to differentiate new lung tumors from those that represent metastasis from other organs to help drive therapeutic decision making. Finally, BarreGEN is used to evaluate mutational load in samples taken from the esophagus to identify patients that are at risk of progressing to esophageal cancer.” As for how these products are implemented and which industry experts the Interpace Diagnostics team approaches, Greg touches on the services and experiences each leader brings to the table and how they use the firm’s products.

“For our Thyroid products, ThyGeNEXT and ThyraMIR, we call primarily on Endocrinologists, ENT’s, Pathologists, Endocrine Surgeons, and Otolaryngologists. We approach them directly via our own Commercial team; identifying them from industry trade conferences and specialty physician databases.

“For pancreatic cancer, we call on Gastroenterologists and specifically those that perform Endoscopic Ultrasound Fine Needle Aspirates of the pancreas. These ‘Endoscopists’ are the primary source of our samples for molecular testing of pancreatic neoplasms. Additionally, we work closely with Pathologists who often perform routine first line tests prior to reflexing to molecular testing and PancraGEN. For BarreGEN, we essentially call on the same constituencies given that the procedure to collect the sample is similar to that used for PancraGEN. For RespriDX, we call on Thoracic Surgeons and Oncologists who focus on Lung cancer as a specialty within the overall oncology market.”

Overall the firm’s mission is to provide important supplemental information following common first line tests to help mitigate diagnostic uncertainty. Providing the firm with the ability and opportunity to fulfil this mission is the innovative, committed and passionate team which forms the backbone of Interpace Diagnostics. When discussing the internal culture, Greg is keen to highlight the significant role the teams play in the overall success of the firm.

“All 100 members of our team are critical to the success of the Company; from our lab Operations team to Client Services, Commercial, and our Corporate Leadership team, we are all focused on our primary mission – to eliminate diagnostic uncertainty and improve patient care and outcomes. We often recognize individuals and teams for extraordinary performance or contributions to a particular focus or priority for the Company.”

Looking ahead to what the future holds for the firm, the team at Interpace Diagnostics hope to build upon their advancements within the industry and their accomplishments, especially following their recent success in Acquisition Intl.’s (AI) Global Excellence Awards 2019 where they were righteously awarded the accolade Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Bringing the interview to a close, Greg signs off by revealing the exciting plans which lie in the pipeline for the firm, noting how the company will complete clinical studies and publish papers in the years to come.

“Moving forward, we will be launching product extensions and expanding indications for some of our current products. In addition, we are starting large-scale studies that will further validate our current products. Lastly, we will also be publishing papers in peer-reviewed publications and will be speaking at and participating in several key industry sponsored conferences including the American Thyroid Association and the American College of Gastroenterology.”

Ultimately, Interpace Diagnostics is consistently growing and at a rapid rate. The future looks promising for the company as they continue to dedicate their time and services to improving patient care through unparalleled insights which have been provided by their proprietary suite of products. As such, Interpace Diagnostics’ success has been a result of the confidence that their customers have in that information.

Company: Interpace Diagnostics

Web Address: www.interpacediagnostics.com

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
Spinal Cord Injuries at Work: Understanding the Long-Term Business and Liability Implications
Legal
29/01/2026Spinal Cord Injuries at Work: Understanding the Long-Term Business and Liability Implications

A spinal cord injury sustained in the workplace is not a single-event incident. It initiates a long-term medical, legal, and financial process that can extend over decades. While paralysis or reduced mobility is often the most visible outcome, secondary compli

Read Full PostRead - Eye Icon
Managing Liability After an Escalator Incident in the Workplace
Legal
26/01/2026Managing Liability After an Escalator Incident in the Workplace

Escalators are an integral part of modern commercial buildings, enabling efficient movement through offices, corporate campuses, and mixed-use facilities. Because they are used daily without incident, their potential risks are often overlooked—until a malfun

Read Full PostRead - Eye Icon
Why Your Company Needs an Asset Management Strategy
News
09/08/2021Why Your Company Needs an Asset Management Strategy

Asset management involves the development, operation, maintenance, and sale of assets efficiently and cost-effectively. All companies need to keep tabs on their assets to allow managers to know where and when to employ different assets to maximise returns. Add

Read Full PostRead - Eye Icon
What Does A Corporate Lawyer Do?
News
04/01/2024What Does A Corporate Lawyer Do?

If you’ve ever considered getting into law then you’re not alone, many high-school graduates go for careers in law due to the high salary and numerous opportunities in the field. But what are the best streams of law to study and what best suits you

Read Full PostRead - Eye Icon
Finix Review: Is This Payment Processor Worth It?
Finance
20/05/2026Finix Review: Is This Payment Processor Worth It?

The question of “is a payment processor worth it” does not have a universal answer. The answer depends on the type of business asking, the stage of the business, and what payments work the business intends to internalise. For a one-person shop sell

Read Full PostRead - Eye Icon
Common Challenges in Property Damage Insurance Claims and How a Lawyer Can Help
News
29/08/2023Common Challenges in Property Damage Insurance Claims and How a Lawyer Can Help

Although the process of filing a property damage insurance claim may seem straightforward in theory, it can often be complex and difficult to navigate in practice, necessitating the expertise of property damage lawyer Houston. From finding the right coverage a

Read Full PostRead - Eye Icon
Dominica Citizenship by Investment: A Path to Caribbean Paradise by Global Residence Index
News
29/12/2023Dominica Citizenship by Investment: A Path to Caribbean Paradise by Global Residence Index

Who does not want to get their dream home in the dreamy landscapes of Dominica, in the paradise of Caribbeans? The island nation of the Caribbean, Dominica, is one of the most unexplored lands. Moreover, the natural hot springs, coastal views, and lively rainf

Read Full PostRead - Eye Icon
Meet the CEOs
Leadership
22/02/2016Meet the CEOs

Meet the CEOs

Read Full PostRead - Eye Icon
ARX Equity Partners completes sale of Fincentrum to Swiss Life
Finance
25/10/2018ARX Equity Partners completes sale of Fincentrum to Swiss Life

Further to regulatory approval, ARX Equity Partners / https://www.arxequity.com (“ARX”) has successfully completed the exit of its investment in Fincentrum / https://www.fincentrum.com, a leading, independent financial advisory business operating in the Cz



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow